Current Report Filing (8-k)
22 März 2023 - 9:01PM
Edgar (US Regulatory)
0001310527
false
0001310527
2023-03-22
2023-03-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (date of earliest event reported): March 22, 2023
QSAM
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
000-41337 |
|
20-1602779 |
(State or other jurisdiction |
|
(Commission File |
|
(IRS Employer |
of incorporation) |
|
Number) |
|
Identification Number) |
9442
Capital of Texas Hwy N, Plaza
1, Suite 500 |
|
78759 |
(Address of principal executive
offices) |
|
(Zip Code) |
|
|
|
Registrant’s telephone
number, including area code |
|
(512) 343-4558 |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD.
On
March 22, 2023, QSAM Biosciences, Inc. (the “Company”) participated in the Emerging Growth Conference. Douglas Baum, our
CEO, presented at the virtual conference, using the presentation furnished as Exhibit 99.1 to this report and incorporated herein by
reference. The Company may use the presentation and/or webcast of the presentation, possibly with modifications, in future presentations
to current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees and others with
an interest in the Company and its business.
A
copy of the presentation may also be made available on the Company’s website at https://ir.qsambio.com/. Materials on the Company’s
website are not part of or incorporated by reference into this report.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall
not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The
following exhibits are filed with this Current Report on Form 8-K:
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
March 22, 2023 |
QSAM Biosciences, Inc. |
|
|
|
|
By: |
/s/ Douglas
Baum |
|
|
Douglas Baum |
|
|
Chief Executive Officer |
Common Stock (QB) (USOTC:QSAM)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Common Stock (QB) (USOTC:QSAM)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Common Stock (QB) (OTCMarkets): 0 Nachrichtenartikel
Weitere Qsam Biosciences, Inc. News-Artikel